The US Patent Trial and Appeal Board on Friday ruled against Danish drugmaker Forward Pharma A/S when it found that Biogen’s patents on its multiple sclerosis drug Tecfidera to be valid, Reuters reported.
The ruling means Bigoen will not have to pay future royalty payments to Forward Pharma.
The companies had been involved in a dispute over patents for dimethyl fumarate, an ingredient in leading oral multiple sclerosis treatment Tecfidera which had sales of about $4 billion in 2016.
The PTAB ruling found Forward’s written patent description to be insufficient to declare infringement by Biogen, Reuters reported.
Under the ruling, Biogen’s Tecfidera exclusivity is secured through 2028.
Forward Pharma said it intended to file an appeal challenging the PTAB’s decision.